|
|
https://mb.cision.com/Public/18595/3698956/a1fc4b3ef46b9029_800x800ar.png
Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab =
Phase 3 Studies in Axial Spondyloarthritis
=C2=B7 Publication of 24week results from the BE MOBILE 1 and BE MOBILE 2 =
studies, evaluating bimekizumab, an IL17A and IL17F inhibitor, across the=
full spectrum of axial... See more |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3694402/b7653f0cf6bf74d6_800x800ar.png
UCBs financial update
=C2=B7 2022 total revenue and adjusted EBITDA margin at the upper end of th=
e guided range
=C2=B7 Cimzia^=C2=AE reached its peak sales target of =E2=82=AC 2bn in 2022
=C2=B7 Fintepla^=C2=AE peak sales expected to reach =E2=82=AC 800 million b=
y 2027
Brussels Belgium, 9 January 2022... See more |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3693925/86e384ee3a575ab3_800x800ar.png
UCB announces rozanolixizumab BLA for the treatment of generalized myast=
henia gravis filed with U.S. FDA and designated for Priority Review
=C2=B7 Biologic License Application BLA designated Priority Review by FDA=
and seeks approval for rozanolixizumab for the treatment of adults with ge=
neralized... See more |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3689260/9662353673d9bc59_800x800ar.png
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
=C2=B7 The FDA designated the BLA resubmission as =E2=80=98Class 2=E2=80=99=
with a sixmonth review period
=C2=B7 The FDA action is expected in Q2 2023=C2=A0
Brussels Belgium, 23 December 2022 =E2=80=93 07:00 CET =E2=80=93 UCB, a=
global... See more |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3686694/bcce151eae89c40e_800x800ar.png
FINTEPLA^=C2=AE=E2=96=BC fenfluramine oral solution recommended for ap=
proval in the EU for adjunctive treatment of seizures associated with Lenno=
xGastaut syndrome LGS
=C2=B7 Recommendation based on Phase 3 study data demonstrating safety and =
efficacy in the most difficult to treat seizure types, including... See more |
|
| |
|
| |
|
|
Search :
